MetaCap

Rhythm Pharmaceuticals Inc. Company Profile

NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

112.36-4.44 (-3.80%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Rhythm Pharmaceuticals at a glance

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Boston, MA. Rhythm Pharmaceuticals is led by Dr. David P. Meeker M.D. and employs about 414 people. The company's shares have traded publicly since 2017.

At a market capitalization of $7.79 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001649904, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Rhythm Pharmaceuticals do?

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Rhythm Pharmaceuticals Inc.
Ticker
NASDAQ: RYTM
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. David P. Meeker M.D.
Employees
414
Headquarters
222 Berkeley Street, Boston, MA, United States
Phone
857 264 4280
IPO year
2017
SEC CIK
0001649904
Latest annual report
10-K · Feb 26, 2026

Companies similar to Rhythm Pharmaceuticals

RYTM peer companies
CompanyPrice% ChgMarket capCompare
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs RYTM
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs RYTM
ALKSAlkermes plc44.94-2.69%$7.55Bvs RYTM
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs RYTM
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs RYTM
PRAXPraxis Precision Medicines Inc.300.43-3.37%$8.40Bvs RYTM
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs RYTM
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs RYTM

Related